top favorite biotech for 2008

Please do your own dd...

Neuren Pharmaceuticals Announces Glypromate Trial Recruits 100th Patient
Thursday January 17, 2008, 9:32 am

Original Announcement: Glypromate trial recruits 100th patient

Neuren Pharmaceuticals announced that its Phase III clinical trial with lead compound Glypromate, in development to reduce cognitive impairment following cardiac surgery, has recruited its 100th patient. This is in line with the trial's objective of completing enrolment by December 2008, as almost all sites are now recruiting. The Data Safety Monitoring Committee will review the patient data of these 100 patients and again at 300 patients in mid-2008.


Neuren Pharma ( NEU.AX)
Marketcap: only 23 million A$
Price: 0,16 A$

News
http://au.finance.yahoo.com/q/aca?s=NEU.AX

Awesome Pipeline :

Glypromate MCI in CABG Phase 3 ongoing
NNZ-2566 Severe TBI(traumatic brain injury)Phase IIa
NNZ-2566 Mild/Mod TBI Phase 2
Motiva Post-stroke-Apathy Phase 2b


Clinical development update 4 Dec 2007:
http://www.neurenpharma.com/images/NEU%20Clinical%20Trials%20Update%20Dec%202007.pdf


Presentation 3 Dec 2007:
http://www.neurenpharma.com/images/Neuren%20AU%20Presentation%20Dec%202007.pdf


Homepage:
http://www.neurenpharma.com/

Taylor Collison
http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf


By the end 1Q CY08, we expect Neuren to be running four major
efficacy trials; namely three Phase 2 trials for NNZ-2566 in
mild/moderate and severe TBI and Motiva� in post stroke abulia/
depression coupled with the current Phase 3 trial for Glypromate� in
CABG. All indications potentially provide Neuren with first to market,
billion dollar opportunities. With a current market cap of $40.2m, Neuren
remains a solid value proposition in the sector, where FDA INDs for mid
to late stage clinical trials continues to remain a vexing proposition. We
maintain our Speculative Buy recommendation and price target of $1.30,
though expect to make changes to our valuation model once the
acquisition has closed, which we expect during the current Q.